<?xml version="1.0" encoding="UTF-8"?>
<billStatus>
  <bill>
    <title>To amend the Federal Food, Drug, and Cosmetic Act to evaluate the potential use of evidence from clinical experience to help support the approval of new indications for approved drugs, and for other purposes.</title>
    <constitutionalAuthorityStatementText><![CDATA[<pre>From the Congressional Record Online through the Government Publishing Office [<a href='http://www.gpo.gov'>www.gpo.gov</a>]By Mr. BURGESS:H.R. 2416.Congress has the power to enact this legislation pursuantto the following:Per Section 8, Clause 1 of the Constitution, Congress shallhave the power to lay and collect taxes. Per the Section 8,Clause 3 of the Constitution, Congress shall have the powerregulate Commerce with foreign Nations and among the severalStates.[Page H3389]</pre>]]></constitutionalAuthorityStatementText>
    <billType>HR</billType>
    <laws />
    <recordedVotes />
    <titles>
      <item>
        <title>To amend the Federal Food, Drug, and Cosmetic Act to evaluate the potential use of evidence from clinical experience to help support the approval of new indications for approved drugs, and for other purposes.</title>
        <parentTitleType />
        <titleType>Official Title as Introduced</titleType>
        <chamberName />
        <chamberCode />
      </item>
      <item>
        <title>To amend the Federal Food, Drug, and Cosmetic Act to evaluate the potential use of evidence from clinical experience to help support the approval of new indications for approved drugs, and for other purposes.</title>
        <parentTitleType />
        <titleType>Display Title</titleType>
        <chamberName />
        <chamberCode />
      </item>
    </titles>
    <originChamber>House</originChamber>
    <amendments />
    <subjects>
      <billSubjects>
        <legislativeSubjects>
          <item>
            <name>Drug safety, medical device, and laboratory regulation</name>
          </item>
          <item>
            <name>Government information and archives</name>
          </item>
          <item>
            <name>Health information and medical records</name>
          </item>
        </legislativeSubjects>
        <policyArea>
          <name>Health</name>
        </policyArea>
      </billSubjects>
    </subjects>
    <introducedDate>2015-05-19</introducedDate>
    <version>1.0.0</version>
    <cosponsors />
    <committees>
      <billCommittees>
        <item>
          <systemCode>hsif00</systemCode>
          <name>Energy and Commerce Committee</name>
          <activities>
            <item>
              <name>Referred to</name>
              <date>2015-05-19T14:03:25Z</date>
            </item>
          </activities>
          <type>Standing</type>
          <subcommittees>
            <item>
              <systemCode>hsif14</systemCode>
              <activities>
                <item>
                  <name>Referred to</name>
                  <date>2015-05-22T19:48:59Z</date>
                </item>
              </activities>
              <name>Health Subcommittee</name>
            </item>
          </subcommittees>
          <chamber>House</chamber>
        </item>
      </billCommittees>
    </committees>
    <actions>
      <actionTypeCounts>
        <billReferrals>1</billReferrals>
        <placeholderTextForH>1</placeholderTextForH>
        <introducedInTheHouse>1</introducedInTheHouse>
        <introducedInHouse>1</introducedInHouse>
      </actionTypeCounts>
      <item>
        <actionDate>2015-05-22</actionDate>
        <committee>
          <name>Health Subcommittee</name>
          <systemCode>hsif14</systemCode>
        </committee>
        <links />
        <sourceSystem>
          <name>House committee actions</name>
          <code>1</code>
        </sourceSystem>
        <text>Referred to the Subcommittee on Health.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2015-05-19</actionDate>
        <sourceSystem>
          <name>House floor actions</name>
          <code>2</code>
        </sourceSystem>
        <committee>
          <name>Energy and Commerce Committee</name>
          <systemCode>hsif00</systemCode>
        </committee>
        <text>Referred to the House Committee on Energy and Commerce.</text>
        <actionCode>H11100</actionCode>
        <type>IntroReferral</type>
        <links />
      </item>
      <item>
        <actionDate>2015-05-19</actionDate>
        <sourceSystem>
          <name>Library of Congress</name>
          <code>9</code>
        </sourceSystem>
        <committee />
        <text>Introduced in House</text>
        <actionCode>Intro-H</actionCode>
        <type>IntroReferral</type>
        <links />
      </item>
      <item>
        <actionDate>2015-05-19</actionDate>
        <sourceSystem>
          <name>Library of Congress</name>
          <code>9</code>
        </sourceSystem>
        <committee />
        <text>Introduced in House</text>
        <actionCode>1000</actionCode>
        <type>IntroReferral</type>
        <links />
      </item>
      <actionByCounts>
        <houseOfRepresentatives>4</houseOfRepresentatives>
      </actionByCounts>
    </actions>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <cboCostEstimates />
    <committeeReports />
    <createDate>2015-05-20T08:46:21Z</createDate>
    <calendarNumbers />
    <latestAction>
      <actionDate>2015-05-22</actionDate>
      <links />
      <text>Referred to the Subcommittee on Health.</text>
    </latestAction>
    <congress>114</congress>
    <updateDate>2017-10-27T18:01:45Z</updateDate>
    <summaries>
      <billSummaries>
        <item>
          <text><![CDATA[<p>This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to establish a program to evaluate the potential use of evidence from clinical experience to support the approval of a new indication for an approved drug and to support post-approval study requirements.</p> <p>&quot;Evidence from clinical experience&quot; means data from sources other than randomized clinical trials, including from observational studies, registries, and therapeutic use.</p> <p>Before implementing the program, the FDA must establish a draft framework for the program that describes current sources of data from clinical experience, gaps in current data collection activities, standards and methodologies for collection and analysis of data from clinical experience, and priority areas, remaining challenges, and potential pilot opportunities that the program will address.</p> The FDA must use the program to inform guidance to industry on the collection and use of evidence from clinical experience.]]></text>
          <lastSummaryUpdateDate>2015-10-28T20:44:12Z</lastSummaryUpdateDate>
          <name>Introduced in House</name>
          <versionCode>00</versionCode>
          <actionDate>2015-05-19</actionDate>
          <actionDesc>Introduced in House</actionDesc>
          <updateDate>2015-05-19T04:00:00Z</updateDate>
        </item>
      </billSummaries>
    </summaries>
    <relatedBills>
      <item>
        <latestTitle>21st Century Cures Act</latestTitle>
        <type>HR</type>
        <congress>114</congress>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
        <number>34</number>
        <latestAction>
          <actionDate>2016-12-13</actionDate>
          <text>Became Public Law No: 114-255.</text>
        </latestAction>
      </item>
    </relatedBills>
    <sponsors>
      <item>
        <bioguideId>B001248</bioguideId>
        <party>R</party>
        <firstName>Michael</firstName>
        <state>TX</state>
        <middleName>C.</middleName>
        <lastName>Burgess</lastName>
        <byRequestType />
        <fullName>Rep. Burgess, Michael C. [R-TX-26]</fullName>
        <district>26</district>
        <identifiers>
          <lisID>1751</lisID>
          <gpoId>8182</gpoId>
          <bioguideId>B001248</bioguideId>
        </identifiers>
      </item>
    </sponsors>
    <notes />
    <billNumber>2416</billNumber>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>

